# Structure and Function of HIV Envelope Glycoprotein: From Entry to Vaccine Immunogen

**ID:** STRUCT-007
**Year:** 2024
**Journals:** PMC; Nature Communications; npj Vaccines
**PubMed:** [PMC7111665](https://pmc.ncbi.nlm.nih.gov/articles/PMC7111665/)

---

## Abstract

The HIV envelope glycoprotein (Env) is the sole viral surface protein mediating cell entry and the primary target for neutralizing antibodies. This comprehensive review covers Env structure, the entry mechanism, vaccine immunogen design (including BG505 SOSIP trimers), and recent 2024 clinical trial advances demonstrating induction of autologous tier-2 neutralizing antibodies in humans.

---

## Key Concepts

- **Env Trimer**: Trimeric spike of gp120-gp41 heterodimers
- **SOSIP**: Stabilized soluble Env trimer design
- **Glycan Shield**: Dense carbohydrate coverage evading immunity
- **Tier-2 Neutralization**: Clinically relevant neutralization sensitivity
- **BG505**: Reference clade A envelope sequence for structural studies

---

## Env Structure Overview

### Trimer Composition
| Component | Function |
|:----------|:---------|
| gp120 | Receptor binding (CD4, coreceptor) |
| gp41 | Membrane fusion machinery |
| Trimer | (gp120-gp41)₃ functional unit |
| Glycans | ~50% of Env mass, immune evasion |

### Structural Organization
```
gp120 → V1/V2/V3/V4/V5 variable loops + conserved core →
    Receptor binding → Conformational change →
        gp41 exposure → Six-helix bundle → Fusion
```

---

## Entry Mechanism

### Sequential Steps
| Step | Event |
|:-----|:------|
| 1 | gp120 binds CD4 on target cell |
| 2 | V1/V2 displacement, V3 exposure |
| 3 | Coreceptor (CCR5/CXCR4) binding |
| 4 | gp41 spring-loaded fusion |
| 5 | Membrane merger, entry |

### V3 Loop and Tropism
| Feature | Significance |
|:--------|:-------------|
| V3 sequence | Determines CCR5 vs CXCR4 usage |
| Charge pattern | X4 tropism associated with positive charge |
| Length | Variable, affects antibody access |

---

## BG505 SOSIP Trimer Design

### Design Elements
| Modification | Purpose |
|:-------------|:--------|
| SOS (A501C-T605C) | Disulfide linking gp120-gp41 |
| IP (I559P) | Stabilizes pre-fusion gp41 |
| SOSIP.664 | Truncation for solubility |
| Furin cleavage | Maintains native structure |

### Structural Fidelity
> "The BG505 SOSIP.664 gp140 protein binds most of the known neutralizing antibodies but generally does not bind antibodies that lack neutralization activity."

### Version Evolution
| Version | Improvement |
|:--------|:------------|
| SOSIP.664 | Prototype (2013) |
| SOSIP.v4 | Enhanced stability |
| SOSIP.v8 | Improved processing |
| SOSIP.v9 | No non-nAb binding, Tm 91°C |

---

## 2024 Clinical Trial: HVTN 137A

### Trial Design
| Parameter | Details |
|:----------|:--------|
| Immunogen | BG505 SOSIP.664 gp140 |
| Adjuvant | 3M-052-AF/Alum (TLR7/8 agonist) |
| Population | Healthy adults (n=17) |
| Design | Randomized, placebo-controlled |

### Results
| Outcome | Finding |
|:--------|:--------|
| Safety | Vaccine appeared safe |
| Trimer-specific antibodies | Robust response |
| B-cell responses | Positive |
| CD4+ T-cell responses | Induced |
| **Tier-2 autologous nAbs** | **5/17 vaccinees** |
| ID50 titers | 1:28 to 1:8647 |

> "Five vaccinees developed serum autologous tier-2 neutralizing antibodies after 2-3 doses targeting C3/V5 and/or V1/V2/V3 Env regions."

---

## Triple Tandem Trimer (TTT) Design (2024)

### Innovation
| Feature | Advantage |
|:--------|:----------|
| Covalently linked trimers | No dissociation |
| Native-like morphology | >85% properly folded |
| Crystal structure obtained | 5.8 Å resolution |

### Comparison
| Format | Oligomer Content |
|:-------|:-----------------|
| SOSIP controls | Dimers + monomers present |
| TTT | **Trimers exclusively** |

---

## Glycan Shield Considerations

### Vaccine Challenges
| Issue | Impact |
|:------|:-------|
| Glycan holes | Immunodominant, strain-specific |
| N241/N289 absence | BG505-specific vulnerability |
| Narrow breadth | Non-broadly neutralizing responses |

### Strategy
> "While glycans play important roles in bNAb responses, holes in the glycan shield appear to dominate the antibody response after vaccination with Env trimer immunogens."

---

## Epitope Landscape

### bnAb Binding Sites
| Epitope | Location | Representative bnAbs |
|:--------|:---------|:---------------------|
| CD4bs | gp120 outer domain | VRC01, 3BNC117 |
| V1/V2 apex | Trimer apex | PG9, CAP256 |
| V3 glycan | High mannose patch | PGT121, 10-1074 |
| MPER | gp41 membrane-proximal | 10E8, 4E10 |
| Interface | gp120-gp41 junction | 35O22, 8ANC195 |

---

## Relevance to Project

HIV Env structure directly informs the Ternary VAE project:
- **Envelope sequences**: Primary target for modeling
- **Variable loops**: Key regions for codon analysis
- **Glycosylation sites**: Sequence constraints (NXS/T)
- **Fitness landscapes**: Entry function as selection pressure

---

*Added: 2025-12-24*
